Mycenax Biotech (4726) — Financial Flexibility Index
Mycenax Biotech (4726) has a Financial Flexibility Index of -0.02x as of September 2025. Free cash flow of NT$-25.73 Million (operating CF NT$-50.35 Million minus capex NT$24.62 Million) represents 0% of total liabilities (NT$1.69 Billion). Also explore 4726 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Mycenax Biotech Financial Flexibility Index (2017–2024)
Historical Financial Flexibility Index trend for Mycenax Biotech across 8 annual periods. Check Mycenax Biotech (4726) strategic investment index to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for Mycenax Biotech (2017–2024)
Year-by-year free cash flow to debt coverage for Mycenax Biotech. For the full company profile including market capitalisation, see 4726 stock market capitalisation.
| Year | Flexibility Index | Free Cash Flow (TWD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.10x | NT$138.83 Million | NT$-191.68 Million | NT$1.34 Billion | ▼ -17.9% |
| 2023 | 0.13x | NT$166.42 Million | NT$-131.18 Million | NT$1.32 Billion | ▼ -64.5% |
| 2022 | 0.35x | NT$476.75 Million | NT$-150.19 Million | NT$1.35 Billion | ▼ -54.2% |
| 2021 | 0.77x | NT$951.86 Million | NT$-146.23 Million | NT$1.23 Billion | ▼ -3.8% |
| 2020 | 0.80x | NT$434.39 Million | NT$174.17 Million | NT$540.89 Million | ▲ +561.3% |
| 2019 | 0.12x | NT$37.17 Million | NT$-140.74 Million | NT$306.04 Million | ▲ +141.6% |
| 2018 | -0.29x | NT$-61.79 Million | NT$-180.27 Million | NT$211.70 Million | ▼ -207.3% |
| 2017 | 0.27x | NT$45.96 Million | NT$-45.55 Million | NT$168.93 Million | — |